Caption Management, LLC Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $3.9 Million - $4.28 Million	100,000 Added 37.04%	370,000 $15.1 Million
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $3.37 Million - $3.57 Million	-82,500 Reduced 23.4%	270,000 $11.4 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $6.08 Million - $12.7 Million	300,000 Added 571.43%	352,500 $14.9 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $455,850 - $717,975	22,500 Added 75.0%	52,500 $1.15 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $478,000 - $707,600	-20,000 Reduced 40.0%	30,000 $953,000
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $15,974 - $24,724	-700 Reduced 1.38%	50,000 $1.22 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $1.29 Million - $1.62 Million	50,700 New	50,700 $1.6 Million
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $1.03 Million - $1.55 Million	-43,800 Reduced 38.83%	69,000 $2.42 Million
Q4 2021 Feb 11, 2022	BUY	$29.21 - $44.64 $1.69 Million - $2.58 Million	57,800 Added 105.09%	112,800 $3.66 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $1.17 Million - $2.14 Million	55,000 New	55,000 $1.62 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.